174 related articles for article (PubMed ID: 37546521)
1. Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type.
Wang Y; Yao F; Chen S; Ouyang X; Lan J; Wu Z; Wang Y; Chen J; Wang X; Chen C
Drug Des Devel Ther; 2023; 17():2259-2271. PubMed ID: 37546521
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
[No Abstract] [Full Text] [Related]
3. Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection.
Lan J; Wu Z; Wang X; Wang Y; Yao F; Zhao BX; Wang Y; Chen J; Chen C
J Pharm Sci; 2022 Jun; 111(6):1833-1842. PubMed ID: 35090867
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and model-based dosing optimization of teicoplanin in elderly critically ill patients with pneumonia.
Kang SW; Jo HG; Kim D; Jeong K; Lee J; Lee HJ; Yang S; Park S; Rhie SJ; Chung EK
J Crit Care; 2023 Dec; 78():154402. PubMed ID: 37634293
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients.
Aulin LBS; De Paepe P; Dhont E; de Jaeger A; Vande Walle J; Vandenberghe W; McWhinney BC; Ungerer JPJ; van Hasselt JGC; De Cock PAJG
Clin Pharmacokinet; 2021 Mar; 60(3):353-363. PubMed ID: 33030704
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients.
Fu WQ; Tian TT; Zhang MX; Song HT; Zhang LL
Front Pharmacol; 2022; 13():1045895. PubMed ID: 36506535
[No Abstract] [Full Text] [Related]
10. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients.
Abdulla A; Rogouti O; Hunfeld NGM; Endeman H; Dijkstra A; van Gelder T; Muller AE; de Winter BCM; Koch BCP
Eur J Clin Pharmacol; 2020 Jul; 76(7):957-967. PubMed ID: 32307575
[TBL] [Abstract][Full Text] [Related]
13. Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information.
Yamada T; Emoto C; Fukuda T; Motomura Y; Inoue H; Ohga S; Ieiri I
Ther Drug Monit; 2022 Jun; 44(3):404-413. PubMed ID: 34629445
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of teicoplanin in children.
Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients.
Zhang T; Sun D; Shu Z; Duan Z; Liu Y; Du Q; Zhang Y; Dong Y; Wang T; Hu S; Cheng H; Dong Y
Front Pharmacol; 2020; 11():594562. PubMed ID: 33363469
[No Abstract] [Full Text] [Related]
17. Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.
Wi J; Noh H; Min KL; Yang S; Jin BH; Hahn J; Bae SK; Kim J; Park MS; Choi D; Chang MJ
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674057
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic/pharmacodynamic target attainment of ceftriaxone 2 g once daily in non-critically ill hospitalized adult patients during the acute phase of infection.
van den Broek AK; van Schip A; Visser CE; Bos JC; Prins JM; van Hest RM
Br J Clin Pharmacol; 2023 Nov; 89(11):3262-3272. PubMed ID: 37309251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
